Good bacteria useful for ulcerative colitis
Posted on: Thursday, 28 July 2005, 16:48 CDT
NEW YORK (Reuters Health) - Consuming a mixture of eight good, or "probiotic," bacteria reduces symptoms in patients with ulcerative colitis that doesn't respond to conventional medications, new research suggests.
Ulcerative colitis is a severe inflammatory disease of the colon that often produces bloody diarrhea and is associated with an increased risk of colon cancer. Complete removal of the colon is frequently performed to reduce the symptoms of the disease and eliminate the cancer risk.
The probiotic mixture, known as VSL#3, contains four strains of Lactobacillus, three strains of Bifidobacterium and one strain of Streptococcus salivarius -- all well-known species of good bacteria.
Although VSL#3 has been shown to maintain remission of ulcerative colitis, there have been no studies on the mixture's use in the active, symptom-producing phase of the disease, co-investigator Dr. Richard N. Fedorak, from the University of Alberta in Edmonton, Canada, and colleagues note in the American Journal of Gastroenterology.
They therefore enrolled 34 patients with active ulcerative colitis who were treated with VSL#3 twice daily for 6 weeks. A variety of standard treatments had been tried on the patients first, all to no avail.
Remission occurred in 53 percent of the patients and an additional 24 percent experienced some degree of improvement in symptoms. A few patients experienced no improvement or worsening of their symptoms.
The only apparent side effect of VSL#3 was increased bloating, reported by 10 patients.
Testing of sampled tissue provided direct evidence that the probiotic bacteria had, in fact, reached the diseased sites of the colon, Fedorak and his team note.
SOURCE: American Journal of Gastroenterology, July 2005.
Source: REUTERS
Related Articles
- Uncovering the Secrets of Ulcer-causing Bacteria
- New Study Finds Cranberry Works As Well As Probiotics in Reducing Ulcer Causing Bacteria
- Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease
- Some Not-So-Obvious Symptoms of the Fragmentation Disease
- Nationwide Survey Reveals Differing Physician and Patient Perceptions Regarding Impact of Ulcerative Colitis on Patients' Lives
- Study Suggests INVEGA(TM) Helps Patients With Schizophrenia Maintain Symptom Control
- Laparoscopic Nissen Fundoplication Offers High Patient Satisfaction With Relief of Extraesophageal Symptoms of Gastroesophageal Reflux Disease
- Data on PEG-INTRON(R) and REBETOL(R) Combination Therapy in Diverse Patient Populations to Be Presented at 2005 Digestive Disease Week (DDW) Meeting
- Odyssey Pharmaceuticals and Indevus Pharmaceuticals Announce Odyssey's Plans to Initiate Phase IV Open Label Study of the Effectiveness and Safety of SANCTURA in Patients With Overactive Bladder Symptoms
- U. Enlists Patients in Clinical Study Linked to Fatal Lung Disease
 |
 |
User Comments (0)
RSS Feeds